Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 2/20 | 0.37 |
| ▸ | RXRB | P28702 | 2/20 | 0.37 |
| ▸ | RXRG | P48443 | 2/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8081384 | 0.86 | LCK (0.38) | THRBCNR2CHRM3 | |
| SCHEMBL2947213 | 0.82 | MIF (0.38) | THRBADORA1MIFPDE4BTRPM8 | |
| SCHEMBL27980530 | 0.80 | KDM4E (0.37) | THRBCNR2MIFPDE4BTRPM8 | |
| SCHEMBL2918546 | 0.80 | TDO2 (0.41) | THRBMAPTADORA1MIFPDE4B | |
| SCHEMBL11922785 | 0.77 | LCK (0.43) | MAPTS1PR4P2RY14 | |
| SCHEMBL2922082 | 0.74 | PDE4D (0.47) | PDE4B | |
| SCHEMBL27980529 | 0.72 | CNR2 (0.34) | CNR2MIFTRPM8CHRM3 | |
| SCHEMBL2921470 | 0.72 | LCK (0.38) | MAPTCNR2 | |
| SCHEMBL11920620 | 0.72 | IKBKB (0.39) | ADORA1MIFRXRARXRBRXRG | |
| SCHEMBL2947373 | 0.72 | PDE4D (0.61) | THRBMAPTS1PR4PDE4BP2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883833-B2 | Substituted benzoazole PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders | DECODE GENETICS EHF (IS) | 2014-11-11 | — | — | US | disclosed |
| US-20140275553-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2014-09-18 | — | — | US | disclosed |
| US-20120207729-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2012-08-16 | — | — | US | disclosed |
| EP-2225215-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | Decode Genetics EHF (IS) | 2010-09-08 | — | — | EP | disclosed |
| EP-2225216-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | Decode Genetics EHF (IS) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009067618-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009067604-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | WO | disclosed |
| US-20090130077-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-21 | — | — | US | disclosed |
| US-20090130076-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130076-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE3B, PDE4B, PDE4A | THRB 3940/4885MAPT 4489/4885ADORA1 498/4885 |
| US-20090130077-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4B, PDE4A, PDE3B | THRB 3629/4885MAPT 3128/4885ADORA1 582/4885 |
| US-20120207729-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE3B, PDE4B, PDE4A | THRB 3940/4885MAPT 4489/4885ADORA1 498/4885 |
| US-20140275553-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE3B, PDE4B, PDE4A | THRB 3940/4885MAPT 4489/4885ADORA1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.